{"id":5858,"date":"2024-11-07T08:14:58","date_gmt":"2024-11-07T14:14:58","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5858"},"modified":"2025-06-27T11:04:05","modified_gmt":"2025-06-27T16:04:05","slug":"renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","title":{"rendered":"El reconocido cirujano de retina y empresario m\u00e9dico Sunil Gupta, MD, se une a la junta directiva de Nanoscope"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5858\" class=\"elementor elementor-5858\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7336a5c0 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"7336a5c0\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-46894e23\" data-id=\"46894e23\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-614fb7bc elementor-widget elementor-widget-text-editor\" data-id=\"614fb7bc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\nDALLAS, 7 de noviembre de 2024. Nanoscope Therapeutics Inc., una empresa de biotecnolog\u00eda en fase cl\u00ednica avanzada que desarrolla terapias g\u00e9nicas para enfermedades retinianas hereditarias y degeneraci\u00f3n macular asociada a la edad (DMAE), anunci\u00f3 hoy que el Dr. Sunil Gupta se ha unido a su Consejo de Administraci\u00f3n. El Dr. Gupta es un cirujano de retina reconocido a nivel nacional y un exitoso emprendedor que aporta una amplia experiencia en todas las fases del desarrollo de f\u00e1rmacos y dispositivos m\u00e9dicos, incluyendo la comercializaci\u00f3n y la fabricaci\u00f3n. \u201cEl Dr. Gupta posee una extraordinaria combinaci\u00f3n de experiencia m\u00e9dica y empresarial en el tratamiento de enfermedades retinianas hereditarias y la DMAE seca. Es un m\u00e9dico de renombre, centrado en el paciente, as\u00ed como un l\u00edder eficaz en la ejecuci\u00f3n de ensayos cl\u00ednicos y operaciones. El Dr. Gupta ha impulsado significativamente la atenci\u00f3n a pacientes con enfermedades de la retina en todo el mundo. Ser\u00e1 un miembro invaluable del Consejo de Nanoscope a medida que avanzamos hacia la comercializaci\u00f3n de nuestras terapias independientes de la mutaci\u00f3n para restaurar la visi\u00f3n en millones de personas ciegas por enfermedades de la retina y DMAE seca\u201d, declar\u00f3 el Dr. Gupta.\u00a0<span class=\"xn-person\">Sulagna Bhattacharya<\/span>, cofundador y director ejecutivo de Nanoscope. \u201cNanoscope contin\u00faa avanzando en el trabajo de sus innovadoras terapias g\u00e9nicas para enfermedades retinianas hereditarias como la retinosis pigmentaria (RP) y la enfermedad de Stargardt, ofreciendo esperanza a pacientes para quienes actualmente no existe cura\u201d, dijo el Dr. Gupta. \u201cLos recientes anuncios de la compa\u00f1\u00eda resaltan los resultados de eficacia y seguridad de su ensayo aleatorizado de fase\u00a0<span class=\"xn-money\">2b<\/span>\u00a0Los ensayos cl\u00ednicos en RP con la posterior presentaci\u00f3n de la BLA son revolucionarios. Con un ensayo de registro de fase 3 para Stargardt y una presentaci\u00f3n de BLA en RP en el horizonte, Nanoscope est\u00e1 m\u00e1s cerca de ayudar a abordar necesidades graves no satisfechas. Nanoscope ha reunido un equipo de clase mundial de cient\u00edficos, m\u00e9dicos y l\u00edderes empresariales, y estoy entusiasmado de contribuir\u201d. \u201cQuiero dar una c\u00e1lida bienvenida al Dr. Gupta y espero trabajar con \u00e9l. Se une a nosotros en un momento crucial en la trayectoria de Nanoscope\u201d, dijo Glenn Sblendorio, presidente de la junta directiva. \u201cCon una v\u00eda regulatoria mejorada, esperamos utilizar su experiencia estrat\u00e9gica, as\u00ed como su red con la comunidad de retina\u201d. El Dr. Gupta es fundador e investigador principal cl\u00ednico en Retina Specialty Institute (RSI), una de las organizaciones de investigaci\u00f3n de retina m\u00e1s grandes de\u00a0<span class=\"xn-location\">los Estados Unidos<\/span>\u00a0atendiendo pacientes en cl\u00ednicas de todo el sur. Tambi\u00e9n fue fundador y director m\u00e9dico de USRetina, una de las asociaciones de m\u00e9dicos retin\u00f3logos m\u00e1s grandes de los Estados Unidos, especializada en distribuci\u00f3n de medicamentos, GPO y procesos operativos cl\u00ednicos y desarrollo de software antes de su reciente venta a McKesson. Fund\u00f3 y se desempe\u00f1a como presidente y director m\u00e9dico de Intelligent Retinal Imaging Systems (IRIS), una plataforma de telemedicina basada en la nube, aprobada por la FDA, para la evaluaci\u00f3n de enfermedades oculares de la retina en el entorno de atenci\u00f3n primaria. El equipo de IRIS del Dr. Gupta est\u00e1 trabajando para acabar con la ceguera prevenible debido a la retinopat\u00eda diab\u00e9tica y otras afecciones en todo el mundo. El Dr. Gupta fue expresidente del Centro de Medicina Deportiva del Instituto Andrews y form\u00f3 parte de la junta del Instituto de Investigaci\u00f3n y Educaci\u00f3n Andrews. En estos esfuerzos y m\u00e1s all\u00e1, conecta la industria y las organizaciones de prestaci\u00f3n de atenci\u00f3n cl\u00ednica para optimizar la experiencia y los resultados de los pacientes. El Dr. Gupta obtuvo su t\u00edtulo de m\u00e9dico de la\u00a0<span class=\"xn-org\">Universidad de Cincinnati<\/span>\u00a0Facultad de Medicina y complet\u00f3 su residencia en Oftalmolog\u00eda en el Cullen Eye Institute en\u00a0<span class=\"xn-org\">Facultad de Medicina de Baylor<\/span>\u00a0en\u00a0<span class=\"xn-location\">Houston, Texas<\/span>. Complet\u00f3 una beca de especializaci\u00f3n en enfermedades y cirug\u00eda vitreorretinianas en la Universidad de Iowa.\n\n<b>Acerca de Nanoscope Therapeutics Inc.<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen y que restauran la visi\u00f3n para los millones de pacientes ciegos por enfermedades degenerativas de la retina, para las cuales no existe cura. El principal activo de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La empresa ha completado el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con Stargardt (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y recientemente\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-us-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration-302247017.html\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 planes para iniciar una Fase 3<\/a>\u00a0Ensayo de registro en el primer trimestre de 2025. MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.\n\n<b>Contacto de inversores:<br class=\"dnr\" \/><\/b>Socios Argot<br class=\"dnr\" \/>(212) 600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a>\n\nFUENTE Terap\u00e9utica del Nanoscopio\n\n<\/div>\n<\/div>\n<\/section><\/article>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>DALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that\u00a0Sunil Gupta, MD, has joined the Company\u2019s Board of Directors. Dr. Gupta is a nationally recognized retinal surgeon and a successful entrepreneur who brings deep experience in all phases [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5861,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5858","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-07T14:14:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors\",\"datePublished\":\"2024-11-07T14:14:58+00:00\",\"dateModified\":\"2025-06-27T16:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"},\"wordCount\":674,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\",\"name\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"datePublished\":\"2024-11-07T14:14:58+00:00\",\"dateModified\":\"2025-06-27T16:04:05+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/NSCOPE_LI_Gupta_V8.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/11\\\/07\\\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El Dr. Sunil Gupta, reconocido cirujano de retina y emprendedor m\u00e9dico, se une al Consejo de Administraci\u00f3n de Nanoscope Therapeutics.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","og_locale":"es_MX","og_type":"article","og_title":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-11-07T14:14:58+00:00","article_modified_time":"2025-06-27T16:04:05+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors","datePublished":"2024-11-07T14:14:58+00:00","dateModified":"2025-06-27T16:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"},"wordCount":674,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","url":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/","name":"El Dr. Sunil Gupta, reconocido cirujano de retina y emprendedor m\u00e9dico, se une al Consejo de Administraci\u00f3n de Nanoscope Therapeutics.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","datePublished":"2024-11-07T14:14:58+00:00","dateModified":"2025-06-27T16:04:05+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/11\/NSCOPE_LI_Gupta_V8.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/11\/07\/renowned-retinal-surgeon-and-medical-entrepreneur-sunil-gupta-md-joins-nanoscope-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5858"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858\/revisions"}],"predecessor-version":[{"id":9027,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5858\/revisions\/9027"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5861"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}